Endocrinology

The randomized trial is the first to assess fecal microbiota transplantation for treating diabetic gastroenteropathy, highlighting its safety and efficacy.

Atumelnant rapidly lowered key biomarkers in congenital adrenal hyperplasia in positive topline results from the Phase 2 TouCAHn trial.

Hyperuricemia was significantly linked to dyslipidemia and hypertriglyceridemia in hospitalized patients with type 2 diabetes, which remained after adjustment.

Our Endocrinology Month in Review for December 2024 highlights recent headlines in diabetes and endocrinology and 4 new episodes of Diabetes Dialogue.

A systematic review and meta-analysis of observational real-world data finds nearly half of patients who begin a GLP-1 RA will discontinue within a year.

A list recapping our most popular endocrinology coverage from the past year.

From groundbreaking therapies to ethical dilemmas, HCPLive’s top podcasts of 2024 delivered expert insights and human stories across medicine.

The FDA's approval marks the second generic approval referencing a GLP-1 receptor agonist in as many months for the agency.

Glycemic control continues to be a major risk factor for diabetic retinopathy, while overweight, obesity, and hypertension are growing in prevalence.

Real-world data from 18,710 MASH patients highlight the impact of comorbidities, biomarkers, and region on mortality, with 70% of deaths CVD-related.

Observational data point to aldosterone dysregulation as an underrecognized risk factor for hypertension and confirm T2D as a known risk factor.

Crinecerfont is indicated to be used with glucocorticoids to control androgen levels in adults and pediatric patients with classic congenital adrenal hyperplasia.

Patients with hypercortisolism and difficult-to-control type 2 diabetes who received mifepristone exhibited a significant HbA1c improvement in the Phase 4 trial.

A look into how SGLT2 inhibitors, GLP-1 RAs, and nsMRAs have redefined the management of cardio-kidney-metabolic diseases.

Data from SURMOUNT-5, a head-to-head trial, demonstrate tirzepatide offered greater weight loss benefits than semaglutide.

Our Endocrinology Month in Review for November 2024 highlights recent headlines in diabetes and endocrinology as well as 5 new episodes of Diabetes Dialogue.

Amgen’s MariTide achieved up to 20% average weight loss at 52 weeks without hitting a plateau in individuals with obesity or overweight.

Reducing systolic blood pressure to less than 120 mmHg lowered the risk of major cardiovascular events for most people with diabetes in the BPROAD trial.

In this episode, hosts discuss the latest developments in GLP-1 receptor agonists, with a particular focus on semaglutide.

The 11 to 3 vote against the benefit-risk profile of sotagliflozin comes with less than 2 months to go until the December 20, 2024 PDUFA date.

SF-36v2 scores also improved by 12 points with semaglutide compared with 6.5 points with placebo.

A decade after bariatric surgery, most teens maintained weight loss and reduced obesity-related conditions such as type 2 diabetes and hypertension.

Richard Pratley, MD, discusses how FLOW mortality data informs the use of semaglutide in patients with chronic kidney disease and type 2 diabetes.

Novo Nordisk will present more detailed data in 2025 and plans to file for an expanded label for Rybelsus for this population.

Brian Hansen, president of CGM at Ascensia Diabetes Care, joins the podcast to discuss the FDA clearance of the Eversense 365 CGM.

The FDA's decision to issue a CRL was announced on October 08, 2024 and cites issues with the timing of the facility inspection.

Time-restricted eating, even without calorie restriction, improved glycemic control and cardiometabolic health in patients with metabolic syndrome.

Our September 2024 monthly recap in endocrinology spotlights regulatory updates, new guidelines, and the latest episodes of Diabetes Dialogue.

A review of 5 highly anticipated FDA decisions expected by year-end, including acoramidis for ATTR-CM, olezarsen for FCS, sotagliflozin for T1D and CKD, and more.

Ascendis Pharma has submitted a sBLA to the FDA for TransCon hGH for the treatment of adults with growth hormone deficiency.